Actos (pioglitazone), sold internationally by the Japanese pharmaceutical company Takeda Pharmaceuticals, has been found to cause bladder cancer in patients. Prescribed to Type II diabetics, Actos is one of the most popular diabetes drugs in the nation. Despite having been recalled in France and banned in many other countries, Actos is still widely used in the United States. Takeda Pharmaceuticals reached a record $6 billion in annual Actos sales and an FDA Actos bladder cancer warning has not deterred the company from marketing the drug. Persons who developed bladder cancer while taking Actos can now file Actos bladder cancer lawsuits. This page provides Actos bladder cancer news from national Actos lawyers.